Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management, but not for thyroid conditions
Patients who begin the at-home protocol concurrent with starting GLP-1 therapy are likely to show meaningfully less facial aging at 12 months than patients who wait for visible changes to appear
Until more targeted research is available, people with active IBD should avoid this product
We choose packaging materials to protect against handling-related damage, moisture exposure, and transportation stress
We maximize your insurance benefits, source manufacturer savings programs, and provide copayment assistance, making semaglutide accessible for all patients
For more information, see the How Repatha works section